Listed

Profound Medical Corp.

PROFNasdaqCIK 1628808HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$2.5mRevenue, Q2 FY2026, three months to 2026-06-30$2.5m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001104659-26-092066.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 6, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$2.5mRevenue, Q2 FY2026, three months to 2026-06-30$2.5m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001104659-26-092066.Report this figure+25.3% on a year earlier
  • Gross margin78.4%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $1.9m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-06, accession 0001104659-26-092066.Revenue: $2.5m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001104659-26-092066.Report this figure−3.3 pts on a year earlier
  • Operating margin−445.7%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$11.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-092066.Revenue: $2.5m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001104659-26-092066.Report this figure+251.3 pts on a year earlier
  • Net margin−384.2%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$9.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-092066.Revenue: $2.5m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001104659-26-092066.Report this figure+408.1 pts on a year earlier
  • Diluted EPS−$0.26Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.26 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001104659-26-092066.Report this figure+50.0% on a year earlier
  • Free cash flownot reported (Capital expenditure not reported)No year-earlier figure to compare

Last eight quarters

Full statements
Revenue$2.5mGross margin 78.4%
Diluted EPS−$0.26, Q2 FY2026
Profound Medical Corp., key figures for the last eight quarters
Line itemUnitperiod not labelled2024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$k2,542Revenue, period not labelled, three months to 2024-09-30$2.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-13, accession 0001104659-25-111378.Report this figure4,026Revenue, Q4 FY2024, three months to 2024-12-31$4.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-07, accession 0001410578-25-000300. Derived: 12-month figure less the 9-month figure.Report this figure2,341Revenue, Q1 FY2025, three months to 2025-03-31$2.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-08, accession 0001410578-25-001112.Report this figure1,981Revenue, Q2 FY2025, three months to 2025-06-30$2.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-14, accession 0001410578-25-001809.Report this figure5,059Revenue, Q3 FY2025, three months to 2025-09-30$5.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-13, accession 0001104659-25-111378.Report this figure6,717Revenue, Q4 FY2025, three months to 2025-12-31$6.7m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-05, accession 0001104659-26-024153. Derived: 12-month figure less the 9-month figure.Report this figure5,337Revenue, Q1 FY2026, three months to 2026-03-31$5.3m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-07, accession 0001104659-26-057198.Report this figure2,483Revenue, Q2 FY2026, three months to 2026-06-30$2.5m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001104659-26-092066.Report this figure
Gross margin%70.3%Gross margin, period not labelled, three months to 2024-09-30. gross profit / revenueGross profit: $1.8m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-13, accession 0001104659-25-111378.Revenue: $2.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-13, accession 0001104659-25-111378.Report this figure73.6%Gross margin, Q4 FY2024, three months to 2024-12-31. gross profit / revenueGross profit: $3.0m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-05, accession 0001104659-26-024153. Derived: 12-month figure less the 9-month figure.Revenue: $4.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-07, accession 0001410578-25-000300. Derived: 12-month figure less the 9-month figure.Report this figure79.2%Gross margin, Q1 FY2025, three months to 2025-03-31. gross profit / revenueGross profit: $1.9m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-07, accession 0001104659-26-057198.Revenue: $2.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-08, accession 0001410578-25-001112.Report this figure81.7%Gross margin, Q2 FY2025, three months to 2025-06-30. gross profit / revenueGross profit: $1.6m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-06, accession 0001104659-26-092066.Revenue: $2.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-14, accession 0001410578-25-001809.Report this figure77.7%Gross margin, Q3 FY2025, three months to 2025-09-30. gross profit / revenueGross profit: $3.9m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-13, accession 0001104659-25-111378.Revenue: $5.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-13, accession 0001104659-25-111378.Report this figure59.4%Gross margin, Q4 FY2025, three months to 2025-12-31. gross profit / revenueGross profit: $4.0m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-05, accession 0001104659-26-024153. Derived: 12-month figure less the 9-month figure.Revenue: $6.7m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-05, accession 0001104659-26-024153. Derived: 12-month figure less the 9-month figure.Report this figure71.8%Gross margin, Q1 FY2026, three months to 2026-03-31. gross profit / revenueGross profit: $3.8m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-07, accession 0001104659-26-057198.Revenue: $5.3m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-07, accession 0001104659-26-057198.Report this figure78.4%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $1.9m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-06, accession 0001104659-26-092066.Revenue: $2.5m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001104659-26-092066.Report this figure
Operating margin%(354.0%)Operating margin, period not labelled, three months to 2024-09-30. operating income / revenueOperating income: −$9.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001104659-25-111378.Revenue: $2.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-13, accession 0001104659-25-111378.Report this figure(207.3%)Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: −$8.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-05, accession 0001104659-26-024153. Derived: 12-month figure less the 9-month figure.Revenue: $4.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-07, accession 0001410578-25-000300. Derived: 12-month figure less the 9-month figure.Report this figure(477.0%)Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$11.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001104659-26-057198.Revenue: $2.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-08, accession 0001410578-25-001112.Report this figure(696.9%)Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$13.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-092066.Revenue: $2.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-14, accession 0001410578-25-001809.Report this figure(176.2%)Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: −$8.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001104659-25-111378.Revenue: $5.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-13, accession 0001104659-25-111378.Report this figure(109.7%)Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: −$7.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-05, accession 0001104659-26-024153. Derived: 12-month figure less the 9-month figure.Revenue: $6.7m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-05, accession 0001104659-26-024153. Derived: 12-month figure less the 9-month figure.Report this figure(150.3%)Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$8.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001104659-26-057198.Revenue: $5.3m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-07, accession 0001104659-26-057198.Report this figure(445.7%)Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$11.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-092066.Revenue: $2.5m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001104659-26-092066.Report this figure
Net margin%(368.4%)Net margin, period not labelled, three months to 2024-09-30. net income / revenueNet income: −$9.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001104659-25-111378.Revenue: $2.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-13, accession 0001104659-25-111378.Report this figure(122.9%)Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: −$4.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-05, accession 0001104659-26-024153. Derived: 12-month figure less the 9-month figure.Revenue: $4.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-07, accession 0001410578-25-000300. Derived: 12-month figure less the 9-month figure.Report this figure(458.1%)Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: −$10.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-092066.Revenue: $2.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-08, accession 0001410578-25-001112.Report this figure(792.3%)Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: −$15.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-092066.Revenue: $2.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-14, accession 0001410578-25-001809.Report this figure(157.7%)Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: −$8.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001104659-25-111378.Revenue: $5.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-13, accession 0001104659-25-111378.Report this figure(121.7%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$8.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-05, accession 0001104659-26-024153. Derived: 12-month figure less the 9-month figure.Revenue: $6.7m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-05, accession 0001104659-26-024153. Derived: 12-month figure less the 9-month figure.Report this figure(132.2%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$7.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-092066.Revenue: $5.3m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-07, accession 0001104659-26-057198.Report this figure(384.2%)Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$9.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-092066.Revenue: $2.5m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001104659-26-092066.Report this figure
Diluted EPS$ per share0.38Diluted EPS, period not labelled, three months to 2024-09-30$0.38 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001104659-25-111378.Report this figurenot reported (Diluted EPS not reported)0.36Diluted EPS, Q1 FY2025, three months to 2025-03-31$0.36 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001104659-26-057198.Report this figure(0.52)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.52 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001104659-26-092066.Report this figure0.26Diluted EPS, Q3 FY2025, three months to 2025-09-30$0.26 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001104659-25-111378.Report this figurenot reported (Diluted EPS not reported)0.19Diluted EPS, Q1 FY2026, three months to 2026-03-31$0.19 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001104659-26-057198.Report this figure(0.26)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.26 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001104659-26-092066.Report this figure
Free cash flow$knot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$16.1mGross margin 70.8%
Diluted EPS$1.41, FY2025
Free cash flow−$38.4m, FY2025
Profound Medical Corp., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m6.9Revenue, FY2021, twelve months to 2021-12-31$6.9m. XBRL concept ifrs-full:Revenue. 40-F filed 2023-03-07, accession 0001410578-23-000212.Report this figure6.7Revenue, FY2022, twelve months to 2022-12-31$6.7m. XBRL concept ifrs-full:Revenue. 40-F filed 2024-03-07, accession 0001410578-24-000149.Report this figure5.9Revenue, FY2023, twelve months to 2023-12-31$5.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-07, accession 0001410578-25-000300.Report this figure9.7Revenue, FY2024, twelve months to 2024-12-31$9.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-07, accession 0001410578-25-000300.Report this figure16.1Revenue, FY2025, twelve months to 2025-12-31$16.1m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-05, accession 0001104659-26-024153.Report this figure
Gross margin%43.0%Gross margin, FY2021, twelve months to 2021-12-31. gross profit / revenueGross profit: $3.0m. XBRL concept ifrs-full:GrossProfit. 40-F filed 2023-03-07, accession 0001410578-23-000212.Revenue: $6.9m. XBRL concept ifrs-full:Revenue. 40-F filed 2023-03-07, accession 0001410578-23-000212.Report this figure45.2%Gross margin, FY2022, twelve months to 2022-12-31. gross profit / revenueGross profit: $3.0m. XBRL concept ifrs-full:GrossProfit. 40-F filed 2024-03-07, accession 0001410578-24-000149.Revenue: $6.7m. XBRL concept ifrs-full:Revenue. 40-F filed 2024-03-07, accession 0001410578-24-000149.Report this figure73.1%Gross margin, FY2023, twelve months to 2023-12-31. gross profit / revenueGross profit: $4.3m. XBRL concept us-gaap:GrossProfit. 10-K filed 2025-03-07, accession 0001410578-25-000300.Revenue: $5.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-07, accession 0001410578-25-000300.Report this figure72.2%Gross margin, FY2024, twelve months to 2024-12-31. gross profit / revenueGross profit: $7.0m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-05, accession 0001104659-26-024153.Revenue: $9.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-07, accession 0001410578-25-000300.Report this figure70.8%Gross margin, FY2025, twelve months to 2025-12-31. gross profit / revenueGross profit: $11.4m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-05, accession 0001104659-26-024153.Revenue: $16.1m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-05, accession 0001104659-26-024153.Report this figure
Operating margin%(440.7%)Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: −$30.3m. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 40-F filed 2023-03-07, accession 0001410578-23-000212.Revenue: $6.9m. XBRL concept ifrs-full:Revenue. 40-F filed 2023-03-07, accession 0001410578-23-000212.Report this figure(480.9%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$32.1m. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 40-F filed 2024-03-07, accession 0001410578-24-000149.Revenue: $6.7m. XBRL concept ifrs-full:Revenue. 40-F filed 2024-03-07, accession 0001410578-24-000149.Report this figure(485.7%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$28.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-07, accession 0001410578-25-000300.Revenue: $5.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-07, accession 0001410578-25-000300.Report this figure(339.4%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$33.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-05, accession 0001104659-26-024153.Revenue: $9.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-07, accession 0001410578-25-000300.Report this figure(256.3%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$41.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-05, accession 0001104659-26-024153.Revenue: $16.1m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-05, accession 0001104659-26-024153.Report this figure
Net margin%(446.7%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −$30.7m. XBRL concept ifrs-full:ProfitLoss. 40-F filed 2023-03-07, accession 0001410578-23-000212.Revenue: $6.9m. XBRL concept ifrs-full:Revenue. 40-F filed 2023-03-07, accession 0001410578-23-000212.Report this figure(429.1%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$28.7m. XBRL concept ifrs-full:ProfitLoss. 40-F filed 2024-03-07, accession 0001410578-24-000149.Revenue: $6.7m. XBRL concept ifrs-full:Revenue. 40-F filed 2024-03-07, accession 0001410578-24-000149.Report this figure(480.1%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$28.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-07, accession 0001410578-25-000300.Revenue: $5.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-07, accession 0001410578-25-000300.Report this figure(285.6%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$27.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-05, accession 0001104659-26-024153.Revenue: $9.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-07, accession 0001410578-25-000300.Report this figure(264.4%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$42.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-05, accession 0001104659-26-024153.Revenue: $16.1m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-05, accession 0001104659-26-024153.Report this figure
Diluted EPS$ per share1.50Diluted EPS, FY2021, twelve months to 2021-12-31$1.50 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 40-F filed 2023-03-07, accession 0001410578-23-000212.Report this figure1.38Diluted EPS, FY2022, twelve months to 2022-12-31$1.38 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 40-F filed 2024-03-07, accession 0001410578-24-000149.Report this figure1.34Diluted EPS, FY2023, twelve months to 2023-12-31$1.34 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-07, accession 0001410578-25-000300.Report this figure1.12Diluted EPS, FY2024, twelve months to 2024-12-31$1.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-05, accession 0001104659-26-024153.Report this figure1.41Diluted EPS, FY2025, twelve months to 2025-12-31$1.41 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-05, accession 0001104659-26-024153.Report this figure
Free cash flow$m(22.4)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −$22.4m. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 40-F filed 2023-03-07, accession 0001410578-23-000212.Capital expenditure: $32.0k. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 40-F filed 2023-03-07, accession 0001410578-23-000212.Report this figurenot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)(38.4)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$38.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-05, accession 0001104659-26-024153.Capital expenditure: $176.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-05, accession 0001104659-26-024153.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Profound Medical Corp.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
FIL Ltd2026-06-30$15.8m2,370,000Added+30,000
GAGNON SECURITIES LLC2026-06-30$13.0m1,960,074Added+15,750
ROYCE & ASSOCIATES LP2026-06-30$8.0m1,199,564Added+83,216
Timelo Investment Management Inc.2026-06-30$7.4m1,114,967Unchanged
Gagnon Advisors, LLC2026-06-30$6.4m962,186Unchanged
Rosalind Advisors, Inc.2026-06-30$5.5m828,118Unchanged
Z3 Capital Partners, LLC2026-06-30$5.5m820,941Added+2,950
LETKO, BROSSEAU & ASSOCIATES INC2026-06-30$5.4m935,725Reduced−17,450
MMCAP International Inc. SPC2026-06-30$4.5m671,356Reduced−73,796
ARDSLEY ADVISORY PARTNERS LP2026-06-30$3.8m575,000Unchanged

Recent filings

All 285 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Profound Medical Corp., recent filings
FiledFormWhat it isAccession number
2026-10-2220:45 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001171843-26-006781
2026-10-1412:00 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001171843-26-006615
2026-10-0917:11 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001171843-26-006559
2026-10-0720:45 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001171843-26-006499
2026-09-0401:00 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001171843-26-005884
2026-09-0311:07 ET8-K5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001171843-26-005868
2026-08-1712:35 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001171843-26-005580
2026-08-1711:30 ET8-K5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001171843-26-005575
2026-08-1320:30 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001171843-26-005500
2026-08-0620:32 ET10-QQuarterly reportPeriod 2026-06-300001104659-26-092066

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Mar 5, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league

About the filer

CIK
1628808
Tickers
PROF
Exchange
Nasdaq
SIC code
3841 Surgical & Medical Instruments & Apparatus
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
A6
Filer category
Non-accelerated filer<br>Smaller reporting company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:44 ET. Listed shows no prices and gives no investment advice.